Academic collaborations for Crescendo

Friday 13 September 2019
Country

United Kingdom

Crescendo Biologics Ltd has entered into collaborations with two UK universities to accelerate development of its lead product for tumours expressing prostate-specific membrane antigen (PSMA). The product, CB307, is due to enter the clinic in 2020.

Separately Crescendo appointed Steward Kay, formerly of GlaxoSmithKline Plc, as its chief business officer.